Xceleron Leads EU Microdose AMS Partnership Programme
News Jan 12, 2006
Xceleron has announced that it has been asked to lead the European Union Microdose AMS Partnership Programme (EUMAPP).
The award of EUR2.1m is confirmation that the EU recognizes the value of microdosing in drug development and that Europe is to play a leading role in the further development of this technology.
The 30-month EUMAPP project gathers together 10 organisations from 5 different countries (United Kingdom, Sweden, Netherlands, France and Poland).
The programme aims to certify high and low voltage Accelerator Mass Spectrometry (AMS) technologies as accurate, reproducible and appropriate methodologies for all measurements required by microdosing studies.
The microdosing approach conducted with AMS offers ways of developing drugs by bridging the gap between the laboratory and the clinic.
The EUMAPP project will contribute to putting Europe at the forefront of microdosing by:
- Demonstrating the reliability of the microdosing approach for predicting drugs' pharmacokinetics (PK) when used at pharmacological doses (from 7 different biopharmaceuticals).
- Certifying AMS as the accurate and appropriate technology for reproducible measurements required by microdosing studies.
- Developing in silico modelling application to predict PK parameters from data derived from microdosing studies.
Professor Colin Garner, Xceleron's CEO commented, "we are delighted to be leading this European consortium which aims to further demonstrate to the pharmaceutical industry the merits of human microdosing as a science driven approach to drug development."
"This programme follows on from the successful CREAM trial and will add 7 more drugs to the growing portfolio of compounds tested by Xceleron."
Fergal Donnelly, MD, Scientific Officer for Biotechnology and Applied Genomics in the European Commission in Brussels, said, "the EUMAPP provides a tremendous opportunity for Europe to maintain its leading role in the field of microdosing."
"Companies of this nature, such as Xceleron, having pioneered human phase 0 microdose studies, will play a vital role in successful exploitation of EU-funded research."
In new studies a novel oxygen-delivery therapeutic restored the function of oxygen-starved heart tissue in an animal model of global hypoxia. Unlike its experimental predecessors, the new drug does not appear to cause systemic side effects or overcorrect with excessive blood oxygenation, which can itself be toxic. Instead, the new drug delivers its precious oxygen cargo only to the tissues that need it most.READ MORE
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE
The sweet flavors’ appeal to teens is a major concern for Food and Drug Administration officials, who recently declared teen vaping an epidemic. New research shows flavorings are transforming more than marketing. The chemical additives react to e-liquid, or e-juice, creating new compounds that could trigger irritation and inflammation when inhaled.READ MORE